Literature DB >> 19605884

Dimensions of design space: a decision-theoretic approach to optimal research design.

Stefano Conti1, Karl Claxton.   

Abstract

Bayesian decision theory can be used not only to establish the optimal sample size and its allocation in a single clinical study but also to identify an optimal portfolio of research combining different types of study design. Within a single study, the highest societal payoff to proposed research is achieved when its sample sizes and allocation between available treatment options are chosen to maximize the expected net benefit of sampling (ENBS). Where a number of different types of study informing different parameters in the decision problem could be conducted, the simultaneous estimation of ENBS across all dimensions of the design space is required to identify the optimal sample sizes and allocations within such a research portfolio. This is illustrated through a simple example of a decision model of zanamivir for the treatment of influenza. The possible study designs include: 1) a single trial of all the parameters, 2) a clinical trial providing evidence only on clinical endpoints, 3) an epidemiological study of natural history of disease, and 4) a survey of quality of life. The possible combinations, samples sizes, and allocation between trial arms are evaluated over a range of cost-effectiveness thresholds. The computational challenges are addressed by implementing optimization algorithms to search the ENBS surface more efficiently over such large dimensions.

Entities:  

Mesh:

Year:  2009        PMID: 19605884     DOI: 10.1177/0272989X09336142

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  11 in total

1.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 2.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

3.  A CTSA agenda to advance methods for comparative effectiveness research.

Authors:  Mark Helfand; Sean Tunis; Evelyn P Whitlock; Stephen G Pauker; Anirban Basu; Jon Chilingerian; Frank E Harrell; David O Meltzer; Victor M Montori; Donald S Shepard; David M Kent
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

4.  Value of Information Analysis in Models to Inform Health Policy.

Authors:  Christopher H Jackson; Gianluca Baio; Anna Heath; Mark Strong; Nicky J Welton; Edward C F Wilson
Journal:  Annu Rev Stat Appl       Date:  2022-03-07       Impact factor: 7.917

5.  Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies.

Authors:  Anna Heath; Natalia Kunst; Christopher Jackson; Mark Strong; Fernando Alarid-Escudero; Jeremy D Goldhaber-Fiebert; Gianluca Baio; Nicolas A Menzies; Hawre Jalal
Journal:  Med Decis Making       Date:  2020-04-16       Impact factor: 2.583

6.  Design of implementation studies for quality improvement programs: an effectiveness-cost-effectiveness framework.

Authors:  Ken Cheung; Naihua Duan
Journal:  Am J Public Health       Date:  2013-11-14       Impact factor: 9.308

7.  Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research.

Authors:  Thea van Asselt; Bram Ramaekers; Isaac Corro Ramos; Manuela Joore; Maiwenn Al; Ivonne Lesman-Leegte; Maarten Postma; Pepijn Vemer; Talitha Feenstra
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

8.  Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial.

Authors:  Anna Heath; Mark Strong; David Glynn; Natalia Kunst; Nicky J Welton; Jeremy D Goldhaber-Fiebert
Journal:  Med Decis Making       Date:  2021-08-13       Impact factor: 2.749

9.  Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.

Authors:  Stijntje W Dijk; Eline M Krijkamp; Natalia Kunst; Cary P Gross; John B Wong; M G Myriam Hunink
Journal:  Value Health       Date:  2022-04-28       Impact factor: 5.101

10.  Prioritisation and design of clinical trials.

Authors:  Anna Heath; M G Myriam Hunink; Eline Krijkamp; Petros Pechlivanoglou
Journal:  Eur J Epidemiol       Date:  2021-06-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.